#4-31E. Steroids in Kawasaki Disease: Rethinking Routine Adjunctive Therapy (NEJM, 2026)

Does the addition of steroids to primary treatment prevent coronary artery lesions in Kawasaki disease? This episode explores the recent "Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease," a multicenter, open-label trial that evaluated the efficacy of adding prednisolone to the standard therapy of intravenous immune globulin (IVIG) and aspirin for acute Kawasaki disease. The results demonstrated that adjunctive prednisolone did not significantly reduce the incidence of coronary artery lesions at one month after illness onset compared to standard treatment alone. The most critical takeaway is that routine, non-selective administration of adjunctive steroids does not decrease coronary complications in an unselected patient population. However, when critically appraising this study, listeners should note that subgroup analyses, such as those evaluating IVIG-resistant patients, were underpowered, meaning a potential benefit in specifically targeted high-risk cohorts cannot be entirely ruled out. For practicing physicians, this study is highly relevant as it reinforces the necessity of appropriate patient stratification rather than adopting a one-size-fits-all approach with steroids in daily clinical practice, ultimately guiding more targeted management of Kawasaki disease.

Citation: Siyuan Lin, et al. Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2511478

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.